Clinical Trials Logo

Neurofibromatosis Type 2 clinical trials

View clinical trials related to Neurofibromatosis Type 2.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05521048 Recruiting - Clinical trials for Neurofibromatosis Type 2

Doxycycline in Cutaneous Schwannoma (NF2)

Start date: September 19, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if successful.

NCT ID: NCT05130866 Recruiting - Clinical trials for Neurofibromatosis Type 2

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

POPLAR-NF2
Start date: June 20, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.

NCT ID: NCT04374305 Recruiting - Meningioma Clinical Trials

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

INTUITT-NF2
Start date: June 20, 2020
Phase: Phase 2
Study type: Interventional

This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. - Investigational Drug Sub-study A: Brigatinib - Investigational Drug Sub-study B: Neratinib